These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 30342955)

  • 1. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
    Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
    Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
    Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
    Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
    Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
    Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
    Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
    Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.
    Prakash TP; Yu J; Migawa MT; Kinberger GA; Wan WB; Østergaard ME; Carty RL; Vasquez G; Low A; Chappell A; Schmidt K; Aghajan M; Crosby J; Murray HM; Booten SL; Hsiao J; Soriano A; Machemer T; Cauntay P; Burel SA; Murray SF; Gaus H; Graham MJ; Swayze EE; Seth PP
    J Med Chem; 2016 Mar; 59(6):2718-33. PubMed ID: 26914862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of modular conjugation strategy for
    Yamamoto T; Sawamura M; Terada C; Kashiwada K; Wada F; Yamayoshi A; Obika S; Harada-Shiba M
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):109-118. PubMed ID: 31617782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry.
    Prakash TP; Brad Wan W; Low A; Yu J; Chappell AE; Gaus H; Kinberger GA; Østergaard ME; Migawa MT; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4127-30. PubMed ID: 26299345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides.
    Nikan M; Tanowitz M; Dwyer CA; Jackson M; Gaus HJ; Swayze EE; Rigo F; Seth PP; Prakash TP
    J Med Chem; 2020 Aug; 63(15):8471-8484. PubMed ID: 32677436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
    Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Metabolite Profiles of an
    Li XQ; Elebring M; Dahlén A; Weidolf L
    Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid.
    Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.
    Yamamoto T; Sawamura M; Wada F; Harada-Shiba M; Obika S
    Bioorg Med Chem; 2016 Jan; 24(1):26-32. PubMed ID: 26678173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides.
    Østergaard ME; Yu J; Kinberger GA; Wan WB; Migawa MT; Vasquez G; Schmidt K; Gaus HJ; Murray HM; Low A; Swayze EE; Prakash TP; Seth PP
    Bioconjug Chem; 2015 Aug; 26(8):1451-5. PubMed ID: 26011654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.